From January 1, 2024 to March 31, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 4,710,870 shares, representing 1.22% for $423.55 million under the buyback announced on October 26, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
113 USD | -0.92% |
|
+1.84% | -8.93% |
07-15 | Morgan Stanley Cuts Price Target on DexCom to $120 From $132, Keeps Equalweight Rating | MT |
07-12 | Stifel Adjusts Price Target on DexCom to $132 From $145 | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.93% | 44.94B | |
-6.46% | 179B | |
-6.43% | 98.84B | |
-7.28% | 65.34B | |
+15.46% | 45.41B | |
+8.19% | 43.76B | |
+12.00% | 29.01B | |
+19.39% | 25.65B | |
-9.09% | 23.32B | |
-12.47% | 21.92B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- Tranche Update on DexCom, Inc.'s Equity Buyback Plan announced on October 26, 2023.